AJ8 Stock Chart & Stats
€6.65
€0.60(11.32%)
At close: 4:00 PM EDT
€6.65
€0.60(11.32%)
Day’s Range― - ―
52-Week Range€2.30 - €8.85
Previous CloseN/A
Volume38.00
Average Volume (3M)36.00
Market Cap
€304.51M
Enterprise Value€391.15M
Total Cash (Recent Filing)€18.74M
Total Debt (Recent Filing)€40.71M
Price to Earnings (P/E)2.8
Beta1.50
Next Earnings
Nov 10, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.72
Shares Outstanding45,161,915
10 Day Avg. Volume60
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio9.24
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.86Price Target Upside228.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.22
Revenue Forecast (FY)€111.59M
Bulls Say, Bears Say
Bulls Say
Initial Product AuthorizationsThe first marketing authorizations for Botvymo and Evamplix create an initial regulatory foothold for Agenus’s immuno-oncology assets. Although limited to Armenia, approval validates the treatment combination and could support future commercialization, partner discussions, and broader regulatory efforts.
Strategic Financing And Pipeline FocusThe financing extends Agenus’s operating runway while concentrating resources on the BOT+BAL program and planned 850-patient ROBBIN Phase 3 trial. This sharper allocation can improve execution focus and preserve the company’s ability to pursue a potentially larger earlier-stage colon cancer opportunity.
Sharp Revenue And Profitability ImprovementThe latest TTM period shows a substantial improvement in reported revenue and a swing to meaningful profitability after several years of losses. If supported by collaboration economics or recurring service activity, this stronger earnings base could improve internal funding capacity and strategic flexibility.
Bears Say
Negative Shareholder EquityNegative shareholder equity reflects accumulated losses and leaves Agenus with a thin capital base despite the reduction in debt. This weakens financial flexibility, increases dependence on external capital, and raises the risk that future funding or restructuring could dilute existing shareholders.
Persistent Cash ConsumptionAgenus continues to consume substantial cash even after improving from the prior year’s burn rate. Persistent negative operating and free cash flow can require repeated financing, limiting strategic flexibility and making the company’s ability to sustain clinical development dependent on outside capital.
Costly Equity-linked Debt FinancingThe loan modification extends maturity to 2029 but preserves a high 13% interest rate and the use of equity to satisfy part of debt obligations. This structure increases financing costs while creating ongoing dilution exposure, adding pressure to capital allocation and shareholder returns.
Agenus News
AJ8 FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was €2.30 and its highest was €8.85 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is €304.51M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 10, 2026 which is in 32 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 06, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of €0.04 by -€0.049.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -0.25.
How many shares outstanding does Agenus have?
Agenus has 45,161,915 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -€0.009 in its last earnings report, missing expectations of €0.04. Following the earnings report the stock price went down -7.092%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in DE:AJ8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.86 (228.71% Upside)
€21.86 (228.71% Upside)
Blogger Sentiment
Bullish
DE:AJ8 Sentiment 69%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.81%
12-Months-Change
Fundamentals
Return on Equity
-38.12%
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AJ8 Stock 12 Month Forecast
Average Price Target
€21.86
▲(228.71% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―